Nathan Thibault

407 total citations
17 papers, 100 citations indexed

About

Nathan Thibault is a scholar working on Physiology, Rheumatology and Organic Chemistry. According to data from OpenAlex, Nathan Thibault has authored 17 papers receiving a total of 100 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 10 papers in Rheumatology and 4 papers in Organic Chemistry. Recurrent topics in Nathan Thibault's work include Lysosomal Storage Disorders Research (14 papers), Glycogen Storage Diseases and Myoclonus (10 papers) and Carbohydrate Chemistry and Synthesis (4 papers). Nathan Thibault is often cited by papers focused on Lysosomal Storage Disorders Research (14 papers), Glycogen Storage Diseases and Myoclonus (10 papers) and Carbohydrate Chemistry and Synthesis (4 papers). Nathan Thibault collaborates with scholars based in United States, United Kingdom and Brazil. Nathan Thibault's co-authors include Kristine C. Willett, Kenneth I. Berger, Priya S. Kishnani, Mark Roberts, David W. Stockton, Barry J. Byrne, Magali Periquet, Juan Clinton Llerena, Sonia S. Maruti and Ans van der Ploeg and has published in prestigious journals such as Journal of Neurology, Frontiers in Genetics and Orphanet Journal of Rare Diseases.

In The Last Decade

Nathan Thibault

16 papers receiving 100 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nathan Thibault United States	6	54	36	27	19	18	17	100
Sonia Segovia Spain	7	77 1.4×	58 1.6×	25 0.9×	12 0.6×	13 0.7×	15	174
Masako Fujiwara Japan	6	64 1.2×	37 1.0×	22 0.8×	14 0.7×	15 0.8×	14	110
Serge Rivera France	5	74 1.4×	27 0.8×	35 1.3×	6 0.3×	11 0.6×	6	127
Lotte Vinge Denmark	7	54 1.0×	50 1.4×	16 0.6×	3 0.2×	12 0.7×	10	179
Silvana De Lucia France	6	18 0.3×	10 0.3×	15 0.6×	8 0.4×	11 0.6×	8	91
Hosny B. Hamed Egypt	6	16 0.3×	14 0.4×	28 1.0×	19 1.0×	9 0.5×	8	113
Pauline Hensman United Kingdom	6	101 1.9×	38 1.1×	51 1.9×	2 0.1×	24 1.3×	9	124
Kyu-Chang Lee South Korea	7	25 0.5×	24 0.7×	46 1.7×	14 0.7×	9 0.5×	12	357
Khan Nedd United States	5	138 2.6×	43 1.2×	69 2.6×	8 0.4×	19 1.1×	6	150
Míriam Almendrote Spain	7	16 0.3×	12 0.3×	37 1.4×	5 0.3×	4 0.2×	18	91

Countries citing papers authored by Nathan Thibault

Since Specialization

Citations

This map shows the geographic impact of Nathan Thibault's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Thibault with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Thibault more than expected).

Fields of papers citing papers by Nathan Thibault

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Thibault. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Thibault. The network helps show where Nathan Thibault may publish in the future.

Co-authorship network of co-authors of Nathan Thibault

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Thibault. A scholar is included among the top collaborators of Nathan Thibault based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Thibault. Nathan Thibault is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Roberts, Mark, Irina Proskorovsky, Patricia Guyot, et al.. (2025). An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease. Advances in Therapy. 42(11). 5578–5599.

Bevilacqua, Jorge A., Hacer Durmuş, Josiah Chai, et al.. (2024). Detection of gene variants associated with recessive limb–girdle muscular weakness and Pompe disease in a global cohort of patients through the application of next-generation sequencing analysis. Frontiers in Genetics. 15. 1477291–1477291. 1 indexed citations

Boentert, Matthias, Kenneth I. Berger, Jordi Díaz‐Manera, et al.. (2024). Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease. Orphanet Journal of Rare Diseases. 19(1). 14–14. 2 indexed citations

Díaz‐Manera, Jordi, Derralynn Hughes, Sevim Erdem‐Özdamar, et al.. (2024). Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials. Molecular Genetics and Metabolism. 143(4). 108608–108608. 1 indexed citations

Byrne, Barry J., Pierre G. Carlier, John Vissing, et al.. (2024). NEO1/NEO-EXT studies: Long-term muscle quantitative magnetic resonance imaging and functional efficacy in adults with late-onset Pompe disease (LOPD) on avalglucosidase alfa treatment. Molecular Genetics and Metabolism. 141(2). 107783–107783. 1 indexed citations

Boentert, Matthias, Shahram Attarian, Jordi Díaz‐Manera, et al.. (2023). Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa. Journal of Neuromuscular Diseases. 11(2). 369–374. 2 indexed citations

Toscano, António, Jérôme Msihid, Nadine A. M. E. van der Beek, et al.. (2023). Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial. Molecular Genetics and Metabolism. 141(2). 108121–108121. 9 indexed citations

Díaz‐Manera, Jordi, Mazen M. Dimachkie, Emmanuelle Salort‐Campana, et al.. (2023). Nonparametric analysis of forced vital capacity in the COMET trial demonstrates superiority of avalglucosidase alfa vs alglucosidase alfa. Molecular Genetics and Metabolism. 138(2). 107077–107077. 1 indexed citations

Broomfield, Alexander, James Davison, Maria Alice Donati, et al.. (2022). Baby-COMET methodology: A clinical study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of avalglucosidase alfa in treatment-naïve participants with IOPD. Molecular Genetics and Metabolism. 135(2). S26–S26. 1 indexed citations

10.

Bevilacqua, Jorge A., Alberto Dubrovsky, Marcondes C. França, et al.. (2020). The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease. Orphanet Journal of Rare Diseases. 15(1). 11–11. 21 indexed citations

11.

Cox, Gerald F., et al.. (2020). Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1. Molecular Genetics and Metabolism Reports. 22. 100552–100552. 6 indexed citations

12.

Thibault, Nathan, Jennifer Ibrahim, Michel Peterschmitt, et al.. (2020). Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. Molecular Genetics and Metabolism. 129(4). 278–285. 5 indexed citations

13.

Stockton, David W., Priya S. Kishnani, Ans van der Ploeg, et al.. (2020). Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. Journal of Neurology. 267(10). 3038–3053. 20 indexed citations

14.

Stockton, David W., Matthias Boentert, Barry J. Byrne, et al.. (2019). Impact of time from diagnosis to treatment on lung function among patients with late-onset Pompe disease: Data from the Pompe registry. Molecular Genetics and Metabolism. 126(2). S140–S140. 1 indexed citations

15.

Valayannopoulos, Vassili, Crystal Sung, Quanhong Lei, et al.. (2019). Alglucosidase alfa inhibitory antibodies and clinical correlates in treatment-naive late-onset Pompe disease patients in the late-onset treatment study (LOTS) over 78 weeks: A new post hoc analysis. Molecular Genetics and Metabolism. 126(2). S146–S147. 1 indexed citations

16.

Martins, Ana María, et al.. (2018). Short stature as a presenting symptom of attenuated Mucopolysaccharidosis type I: case report and clinical insights. BMC Endocrine Disorders. 18(1). 83–83. 8 indexed citations

17.

Thibault, Nathan, et al.. (2016). Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review. American Journal of Therapeutics. 25(3). e333–e338. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact